Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 751

1.

Impact of single room contact precautions on hospital-acquisition and transmission of multidrug-resistant Escherichia coli: a prospective multicentre cohort-study in haematological and oncological wards.

Biehl LM, Higgins P, Wille T, Peter K, Hamprecht A, Peter S, Dörfel D, Vogel W, Häfner H, Lemmen S, Panse J, Rohde H, Klupp EM, Schafhausen P, Imirzalioglu C, Falgenhauer L, Salmanton-García J, Stecher M, Vehreschild JJ, Seifert H, Vehreschild MJGT.

Clin Microbiol Infect. 2019 Jan 11. pii: S1198-743X(18)30840-1. doi: 10.1016/j.cmi.2018.12.029. [Epub ahead of print]

PMID:
30641228
2.

Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis.

Amaral T, Tampouri I, Eigentler T, Keim U, Klumpp B, Heinrich V, Zips D, Paulsen F, Gepfner-Tuma I, Skardelly M, Tatagiba M, Tabatabai G, Garbe C, Forschner A.

Immunotherapy. 2019 Jan 4. doi: 10.2217/imt-2018-0149. [Epub ahead of print]

PMID:
30606066
3.

Mechanisms of Tumor-Induced Lymphovascular Niche Formation in Draining Lymph Nodes.

Commerford CD, Dieterich LC, He Y, Hell T, Montoya-Zegarra JA, Noerrelykke SF, Russo E, Röcken M, Detmar M.

Cell Rep. 2018 Dec 26;25(13):3554-3563.e4. doi: 10.1016/j.celrep.2018.12.002.

4.

An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring system.

Larkin J, Brown MP, Arance AM, Hauschild A, Queirolo P, Vecchio MD, Ascierto PA, Krajsová I, Schachter J, Neyns B, Garbe C, Sileni VC, Mandalà M, Gogas H, Espinosa E, Hospers G, Lorigan P, Nyakas M, Guminski A, Liszkay G, Rutkowski P, Miller W Jr, Donica M, Makrutzki M, Blank C.

Eur J Cancer. 2019 Jan;107:175-185. doi: 10.1016/j.ejca.2018.11.018. Epub 2018 Dec 20.

PMID:
30580112
5.

Modifiable Risk-factors for Keratinocyte Cancers in Australia: A Case-control Study.

Serna-Higuita LM, Harrison SL, Buttner P, Glasby M, Raasch BA, Iftner A, Garbe C, Martus P, Iftner T.

Acta Derm Venereol. 2018 Dec 13. doi: 10.2340/00015555-3107. [Epub ahead of print]

6.

Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?

Grob JJ, Garbe C, Ascierto P, Larkin J, Dummer R, Schadendorf D.

Lancet Oncol. 2018 Dec;19(12):e720-e725. doi: 10.1016/S1470-2045(18)30596-5. Review.

PMID:
30507438
7.

Lack of survival benefit in sentinel lymph node-positive melanoma with immediate complete lymphadenectomy - a review.

Stadler R, Leiter U, Garbe C.

J Dtsch Dermatol Ges. 2019 Jan;17(1):7-13. doi: 10.1111/ddg.13707. Epub 2018 Dec 3. Review.

PMID:
30506865
8.

Nuclear Translocation of Argonaute 2 in Cytokine-Induced Senescence.

Rentschler M, Chen Y, Pahl J, Soria-Martinez L, Braumüller H, Brenner E, Bischof O, Röcken M, Wieder T.

Cell Physiol Biochem. 2018;51(3):1103-1118. doi: 10.1159/000495490. Epub 2018 Nov 26.

9.

6- and 8-Prenylnaringenin, Novel Natural Histone Deacetylase Inhibitors Found in Hops, Exert Antitumor Activity on Melanoma Cells.

Venturelli S, Niessner H, Sinnberg T, Berger A, Burkard M, Urmann C, Donaubauer K, Böcker A, Leischner C, Riepl H, Frank J, Lauer UM, Garbe C, Busch C.

Cell Physiol Biochem. 2018;51(2):543-556. doi: 10.1159/000495275. Epub 2018 Nov 20.

10.

BRAF mutation testing in melanoma: results from a German observational multicenter study.

Hartmann A, Schirmacher P, Sterlacci W, Koch W, Liesenfeld DB, Schif B, Garbe C.

Virchows Arch. 2019 Jan;474(1):71-78. doi: 10.1007/s00428-018-2480-4. Epub 2018 Nov 7.

PMID:
30406424
11.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, Wainstein A, Caglevic C, Lorigan P, Gogas H, Alvarez M, Duncombe R, Lebbe C, Peris K, Rutkowski P, Stratigos A, Forsea AM, De La Cruz Merino L, Kukushkina M, Dummer R, Hoeller C, Gorry C, Bastholt L, Herceg D, Neyns B, Vieira R, Arenberger P, Bylaite-Bucinskiene M, Babovic N, Banjin M, Putnik K, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Ymeri A, Stojkovski I, Garbe C.

Eur J Cancer. 2018 Nov;104:201-209. doi: 10.1016/j.ejca.2018.09.013. Epub 2018 Oct 31.

PMID:
30388700
12.

Time Trends in Incidence and Mortality of Cutaneous Melanoma in Germany.

Garbe C, Keim U, Eigentler T, Amaral T, Katalinic A, Holleczek B, Martus P, Leiter U.

J Eur Acad Dermatol Venereol. 2018 Nov 2. doi: 10.1111/jdv.15322. [Epub ahead of print]

PMID:
30387899
13.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM.

Eur J Cancer. 2018 Nov;104:137-144. doi: 10.1016/j.ejca.2018.09.017. Epub 2018 Oct 20.

PMID:
30347289
14.

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study.

Tietze JK, Forschner A, Loquai C, Mitzel-Rink H, Zimmer L, Meiss F, Rafei-Shamsabadi D, Utikal J, Bergmann M, Meier F, Kreuzberg N, Schlaak M, Weishaupt C, Pföhler C, Ziemer M, Fluck M, Rainer J, Heppt MV, Berking C.

Oncotarget. 2018 Sep 28;9(76):34336-34346. doi: 10.18632/oncotarget.26149. eCollection 2018 Sep 28.

15.

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT.

Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Erratum in: Lancet Oncol. 2018 Oct;19(10):e509.

PMID:
30219628
16.

Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy.

Zelba H, Bochem J, Pawelec G, Garbe C, Wistuba-Hamprecht K, Weide B.

Cancer Immunol Immunother. 2018 Sep 14. doi: 10.1007/s00262-018-2244-7. [Epub ahead of print]

PMID:
30218171
17.

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.

Long GV, Tykodi SS, Schneider JG, Garbe C, Gravis G, Rashford M, Agrawal S, Grigoryeva E, Bello A, Roy A, Rollin L, Zhao X.

Ann Oncol. 2018 Nov 1;29(11):2208-2213. doi: 10.1093/annonc/mdy408.

18.

Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs.

Makino E, Gutmann V, Kosnopfel C, Niessner H, Forschner A, Garbe C, Sinnberg T, Schittek B.

Cell Death Dis. 2018 Sep 11;9(9):930. doi: 10.1038/s41419-018-0952-8.

19.

Fear of cancer progression in patients with stage IA malignant melanoma.

Wagner T, Augustin M, Blome C, Forschner A, Garbe C, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Terheyden P, Mueller-Brenne T, Kähler KC.

Eur J Cancer Care (Engl). 2018 Sep;27(5):e12901. doi: 10.1111/ecc.12901. Epub 2018 Aug 20.

PMID:
30126009
20.

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma.

Simon B, Wiesinger M, März J, Wistuba-Hamprecht K, Weide B, Schuler-Thurner B, Schuler G, Dörrie J, Uslu U.

Int J Mol Sci. 2018 Aug 11;19(8). pii: E2365. doi: 10.3390/ijms19082365.

Supplemental Content

Loading ...
Support Center